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Application of a Physiologically-Based Pharmacokinetic Model for the Prediction of 
Bumetanide Plasma and Brain Concentrations in the Neonate 
Abstract  
Bumetanide is a loop diuretic that is proposed to possess a beneficial effect on disorders of 
the central nervous system, including neonatal seizures. Therefore, prediction of unbound 
bumetanide concentrations in brain is relevant from a pharmacological prospective. A 
physiologically-based pharmacokinetic (PBPK) model was developed for the prediction of 
bumetanide disposition in plasma and brain in adult and pediatric populations. 
A compound file was built for bumetanide integrating physicochemical data and in vitro data. 
Bumetanide concentration profiles were simulated in both plasma and brain using Simcyp 
PBPK model. Simulations of plasma bumetanide concentrations were compared against 
plasma levels published in literature. The model performance was verified with data from 
adult studies before predictions in the pediatric population were undertaken.  
The adult and pediatric intravenous models predicted pharmacokinetic factors, namely area 
under the concentration-time curve, maximum concentration in plasma and time to maximum 
plasma concentration, within two-fold of observed values. However, predictions of plasma 
concentrations within the neonatal intravenous model did not produce a good fit with 
observed values.  
The PBPK approach used in this study produced reasonable predictions of plasma 
concentrations of bumetanide, except in the critically ill neonatal population. This PBPK 
model requires more information regarding metabolic intrinsic clearance and transport 
parameters prior to further validation of drug disposition predictions in the neonatal 
population. Given the lack of information surrounding certain parameters in this special 
population, the model is not appropriately robust to support the recommendation of a suitable 
dose of bumetanide for use as an adjunct antiepileptic in neonates.  
ClinicalTrials.gov trial registry, NCT01434225 
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Abbreviations 
AUC: area under the concentration-time curve; BBB: blood-brain barrier; Cl: clearance; 
CLint: hepatic intrinsic clearance; Cmax: peak plasma concentration;  CNS: central nervous 
system; fu: fraction unbound; IV: intravenous; Kp,brain: brain-to-plasma partition coefficient; 
MRP4: multidrug resistance protein 4; NKCC1: Na-K-Cl cotransporter; OAT3: organic anion 
transporter 3; Oatp1a4: organic anion-transporting polypeptide 1a4; Obs: observed; PBPK: 
physiologically-based pharmacokinetic modeling; Pred: predicted; tmax: time to reach peak 
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Introduction 
Bumetanide is an inhibitor of Na-K-2Cl cation chloride cotransporter (NKCC1) that was 
initially developed as a loop diuretic for the treatment of edema in adults and children (Cook 
et al., 1988; Holazo, Colburn, Gustafson, Young, & Parsonnet, 1984; Lau, Hyneck, Berardi, 
Swartz, & Smith, 1986; Marcantonio et al., 1982; Marshall, Wells, Letzig, & Kearns, 1998; 
Oberbauer, Krivanek, & Turnheim, 1995). It had been suggested that bumetanide may be 
used as an adjunct antiepileptic with phenobarbital in the treatment of neonatal seizures and a 
dose-finding clinical trial of bumetanide has been undertaken in a critically ill neonatal cohort 
(Dzhala, Brumback, & Staley, 2008; Pressler et al., 2015). The mechanism underlying 
bumetanide’s adjunct antiepileptic activity has been elucidated to be due to the inhibition of 
intracellular chloride accumulation through NKCC1, thereby facilitating the excitatory to 
inhibitory switch in gamma-aminobutyric acid signaling (Ben-Ari, 2002). However, 
permeability of bumetanide across the blood-brain barrier (BBB) has been predicted and 
shown experimentally to be a limiting factor,  as it is a highly plasma protein bound, diprotic 
acid with pKa values of 3.6 and 7.7 (Fiori et al., 2003), therefore is >99% ionized at 
physiological pH and bumetanide has been shown to be a substrate of human organic anion 
transporter 3 (OAT3), murine organic anion-transporting polypeptide 1a4 (Oatp1a4) and 
human multidrug resistance protein 4 (MRP4), which all operate as efflux transporters at the 
BBB at physiological pH (Donovan, O'Brien, Boylan, Cryan, & Griffin, 2015; M. D. 
Donovan, H. Schellekens, G. B. Boylan, J. F. Cryan, & B. T. Griffin, 2016; Puskarjov, Kahle, 
Ruusuvuori, & Kaila, 2014; Römermann et al., 2017). Despite knowing that the half-maximal 
inhibitory concentration of bumetanide for NKCC1 is between 200 and 300nM, it is unknown 
if, and at what systemic dose, this unbound concentration of bumetanide in the brain can be 
achieved (Puskarjov et al., 2014).  
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Bumetanide is not licensed for use in the pediatric population as ‘no clinical trials have been 
carried out in children’, but its use has been reported in critically ill edematous children 
(Health Products Regulatory Authority, 2016; Marshall et al., 1998; Sullivan, Witte, 
Yamashita, Myers, & Blumer, 1996). Bumetanide pharmacokinetics in healthy adult 
volunteers have been described; absorption following oral administration occurs rapidly, with 
a reported bioavailability of 95% and the maximum plasma concentration measured by two 
hours post dosing (Ward & Heel, 1984). Bumetanide is highly plasma-protein bound (up to 
95%), but the range of volumes of distribution is nonetheless large (12-35 litres). The 
elimination half-life of bumetanide is approximately 1.25 hours. Half of the administered 
dose is eliminated unchanged in urine, with hepatic metabolism and biliary excretion 
accounting for the remainder of the excretion (Halladay, Carter, Glenn Sipes, Brodie, & 
Bressler, 1975; Ward & Heel, 1984). The main Phase I metabolic route for bumetanide is 
oxidation of the N-butyl side chain forming inactive alcohol metabolites. Glucuronidation by 
UDP-glucuronosyl transferase occurs prior to excretion in the urine and bile (Zisaki, 
Miskovic, & Hatzimanikatis, 2015). It has been estimated that up to 20% of the dose is 
excreted via the feces (Halladay et al., 1975). Age is a major source of variability in all 
aspects of pharmacokinetics, including absorption, distribution, metabolism and elimination, 
and any of the above pharmacokinetic processes could potentially lead to inter-population 
(adults vs neonates) variation due to developmental changes (Marshall, Wells, Letzig, & 
Kearns, 1998). Despite these potentially large pharmacokinetic differences, legislation 
requiring pediatric clinical drug trials to be conducted is relatively new (Leong et al., 2012).  
The extensive practice of off-label prescribing in the pediatric population not only leads to a 
higher risk of adverse drug reactions, but also to low levels of efficacy due to suboptimal 
dosing of the therapeutic agent (Leong et al., 2012). One of the reasons for this is that 
maturation of pharmacokinetic processes, such as metabolism and elimination, are not linear 
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with age or bodyweight, thus allometric scaling of adult drug doses to pediatric dosing 
regimens results in unpredictable and often inaccurate pediatric doses (Espie, Tytgat, 
Sargentini-Maier, Poggesi, & Watelet, 2009; T. N. Johnson, Rostami-Hodjegan, & Tucker, 
2006). Allometric scaling methods, including bodyweight, the three-quarters exponent of 
bodyweight and body surface area, have been shown to both over- and under-predict suitable 
doses across the pediatric dose range, emphasizing that children are not just small adults 
(Bouzom & Walther, 2008; T. N. Johnson, 2008). Conversely, the physiologically-based 
pharmacokinetic (PBPK) approach, which integrates both physicochemical properties of the 
drug and physiological properties in a physiologically relevant compartmental structure, has 
demonstrated usefulness in the prediction of drug pharmacokinetics and inter-individual 
variability (Nestorov, 2003; Rostami-Hodjegan, 2012; Sager, Yu, Ragueneau-Majlessi, & 
Isoherranen, 2015). When applied to a pediatric population, the system properties are 
parameterized with age-dependent physiological parameters, such as tissue volumes and 
enzyme ontogeny (T. N. Johnson & Rostami-Hodjegan, 2011).  
PBPK models are reported to produce superior predictions of concentration-time profiles 
compared to classic compartmental models, but are burdened by many disadvantages also, 
such as the need for detailed physiological and drug data which may not be readily available 
(Bouzom & Walther, 2008; Sager et al., 2015). The PBPK model can be used to predict drug 
exposure in different tissues as it encompasses each organ as a separate compartment, 
including inaccessible compartments such as the brain (Sager et al., 2015). In this study, a 
PBPK model is employed to predict the concentration-time profiles produced by bumetanide 
in plasma in the adult population and extend it to pediatric population. Validations of these 
predictions are based on human data which has been published and is available in the 
literature. One of the main aims of this research was to predict the concentration of 
bumetanide achieved in the brain compartment of a simulated neonatal population. Ideally, 
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observed brain or cerebrospinal fluid (CSF) concentrations would be compared with 
predicted values in adults initially, if available, prior to predicting brain/CSF concentrations 
in neonates. This would improve confidence in the predictions made (Maharaj, Barrett, & 
Edginton, 2013). CSF sampling in adults of bumetanide concentration is unlikely to be 
feasible or ethical, as the treatment of seizures with bumetanide is particular to pediatric 
populations.  Nonetheless, the maximum concentrations achieved in brain in the neonatal 
population can be estimated; however the reliability of this data is weak, as brain/CSF 
predictions were not validated in an adult population first and CSF samples were not taken 
from the neonatal study of bumetanide, NEMO (Treatment of NEonatal seizures 
with Medication Off-patent: evaluation of efficacy and safety of bumetanide, 
Clinicaltrials.gov identifier - NCT 01434225). This bumetanide PBPK model will enrich our 
understanding of the mechanisms that underpin the pharmacokinetic differences seen 
between adults and neonates. This study shows the usefulness of in silico predictions in 
bridging between preclinical in vitro and in vivo experiments to first-in-neonate trials in the 
context of this particular clinical situation (bumetanide in critically-ill neonates with 
seizures).    
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Materials and Methods 
Model structure 
Simcyp Simulator V14 (Simcyp Ltd, Sheffield, UK) was used to provide the general structure 
of the developed PBPK model. The 4-compartmental permeability-limited brain 4brain 
model which is  incorporated into the human whole body PBPK model of the Simcyp 
Simulator and has been described previously (Gaohua, Neuhoff, Johnson, Rostami-Hodjegan, 
& Jamei, 2016) was used to predict drug concentrations in the central nervous system (CNS) 
for this study. Simcyp
®
 is a population-based simulator that performs ‘bottom-up’ 
mechanistic modeling and simulation of absorption, distribution, metabolism and excretion 
processes to predict pharmacokinetic profiles and parameters of drugs and their variation 
between virtual subjects (Jamei et al., 2009).  
Model development 
The model of bumetanide was developed as described in Figure 1. The human PBPK model 
was used to predict bumetanide concentrations in a virtual adult population of healthy 
volunteers divided into ten trials with ten patients in each trial. Pharmacokinetic parameters 
from the simulated trials were compared with actual published plasma data from healthy 
volunteer adults from a total of five different studies (Cook et al., 1988; Holazo et al., 1984; 
Lau et al., 1986; Marcantonio et al., 1982; Oberbauer et al., 1995). The developed model was 
ultimately used to predict the pharmacokinetics of bumetanide using Simcyp’s Paediatric 
PBPK model, which was checked for accuracy using plasma samples collected from two 
trials, one involving a heterogeneous population of nine children with edema (ranging from 3 
months to 11.5 years, with one participant aged 25 years) and the NEMO clinical study with 
fourteen critically-ill neonates with seizures (Marshall et al., 1998; Pressler et al., 2015; US 
National Institutes of Health, 2015). Simulated trial designs, including the age ranges, 
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male/female ratios and dosing schedules for each respective virtual trial were based on 
published clinical trials. 
Relevant physicochemical properties of bumetanide such as molecular weight, lipophilicity, 
ionization constants, and fraction unbound in plasma were collated from publications and 
entered as model inputs (Table 1). Total intravenous clearance of bumetanide was calculated 
as the mean of the intravenous clearance reported in three studies, weighted based on sample 
size (Marcantonio et al., 1982; Oberbauer et al., 1995; Pentikainen, Pasternack, Lampainen, 
Neuvonen, & Penttila, 1985).  Tissue partition coefficients of bumetanide were calculated 
using the Rodgers and Rowland algorithm (Simcyp Kp prediction method 2) (Rodgers & 
Rowland, 2007). The brain: plasma partition coefficient (Kp brain) was manually changed 
from that predicted by the Rodgers and Rowland method from physicochemical properties of 
bumetanide (0.058) to values reported in rodents (0.01 in adult rats, 0.015 in adult mice, 0.06-
0.26 in both adult and juvenile rats with seizures induced using different seizure models 
(Brandt, Nozadze, Heuchert, Rattka, & Loscher, 2010; Donovan et al., 2015; Tollner, Brandt, 
Romermann, & Loscher, 2015). There are a number of limitations with the predictions of 
bumetanide concentrations in brain: large interindividual variability in observed plasma 
concentrations makes it very difficult to compare the concentrations predicted by the model 
with observed concentrations; there are differences between the predicted Kp brain values 
based on physicochemical properties and observed Kp brain values in rodents; the 
translatability of rodent data such as Kp brain to humans, especially critically ill neonates, may 
not be accurate (Zamek-Gliszczynski et al., 2013) and Kp brain in critically ill neonates is 
unknown. Thus, the prediction of bumetanide concentrations in brain is a theoretical exercise 
to explore if predicted concentrations are in the effective range. All available Kp brain values 
were used to predict brain concentration. The default physiological parameters for healthy 
adult volunteers and pediatric populations were used. The pediatric population within Simcyp 
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Simulator has extensive information on pediatric demography, developmental physiology and 
biochemistry built into it (T. N. Johnson, Zhou, & Bui, 2014). Due to the lack of quantitative 
in vitro data on the hepatic metabolism of bumetanide, hepatic intrinsic clearance was back 
calculated from the weighted mean of adult intravenous clearance using the retrograde model 
available in the Simcyp Simulator. Once the hepatic clearance is established in adult, then the 
adult hepatic intrinsic clearance is scaled to neonates based on the blood flow, liver size, 
protein binding and ontogeny in children. Thus, a perfusion-limited model incorporating 
adult clearance values was utilizsed for adult and pediatric simulations.  
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Model verification 
Simulated trials yielded predictions of both pharmacokinetic parameters and concentration-
time profiles. Pharmacokinetic parameter predictions were compared against observed values 
expressed in the literature. Predictions of pharmacokinetic parameters within two-fold of the 
observed value were considered to be reasonable predictions, as this is a frequently used 
criterion for accuracy (Musther et al., 2015).  Predicted concentration-time profiles were 




 percentile confidence intervals. Visual predictive checks 
against the observed mean concentrations ± standard deviations were used to confirm the 
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Results 
Model Simulations of Plasma Bumetanide in Adult Populations 
In humans, the PBPK model of bumetanide was verified in healthy adult volunteers using 
intravenous data (Table 2 and Figure 2). The simulated output demonstrated a two-
compartment profile, consistent with published pharmacokinetic models (Jullien et al., 2015; 
Marcantonio et al., 1982; Popovic et al., 2013). Simulations of intravenous bolus injections 
generated reasonable pharmacokinetic predictions of area under the concentration-time curve 
(AUC) (0.71-1.15), peak plasma concentration (Cmax) (0.62-1) and time to reach peak 
plasma concentration (tmax) (0.5-1) as shown by the predicted/observed ratios (Table 2) and 
concentration-time profiles overlaid the observed data (Figure 2). As intravenous clearance 
differed between studies, a weighted mean of clearance was calculated from these studies 
based on sample size (Marcantonio et al., 1982; Oberbauer et al., 1995; Pentikainen et al., 
1985). Renal clearance values were similar across all studies, so a mean value was chosen 
(Marcantonio et al., 1982; Oberbauer et al., 1995). The predictions made using the Simcyp 
model were within two-fold of observed values in adults, which meets the criteria for 
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Model Simulations of Plasma Bumetanide in Pediatric Populations 
A pediatric PBPK model for bumetanide was developed using a similar approach to the adult 
model, this time using the in-built pediatric population in Simcyp
®
. The pharmacokinetic 
parameters estimated by the pediatric intravenous model are compared to observed values 
(Table 3 and Figure 3). The predicted pharmacokinetic parameters from a single intravenous 
dose of bumetanide in a virtual pediatric population comprising ten trials with ten patients 
each reflected observed data from a heterogeneous edematous pediatric population well with 
predicted/observed ratios for AUC, Cmax and tmax calculated as 1, 1.39 and 1 respectively. 
Bumetanide plasma levels in neonates were shared with us by the consortium of NEMO trial 
members, and were used to compare to predicted bumetanide profiles in a virtual neonatal 
population (Table 4 and Figure 4) (Jullien et al., 2015; Pressler et al., 2015). Since the true 
ontogeny is unknown, both the fast ontogeny and slow ontogeny scenario were explored. The 
slow ontogeny function within Simcyp
®
 was used to scale clearance of bumetanide to the 
pediatric population. However, AUC, Cmax and tmax predicted by the neonatal model fell 
outside of acceptable limits in certain instances, which could be due to a number of reasons. 
The observed AUC was taken as the range (1.9-17.7 mg/L.h) reported for AUC of the first 
bumetanide dose which represents a 9.3-fold difference between maximum and minimum 
observed AUC, reflecting the large inter-individual variability in this critically ill neonatal 
population (Jullien et al., 2015). Moreover, there is wide variability between the predicted: 
observed ratios for Cmax (0.87-2.24) and tmax (0.76-2.4) depending on the dose. This may 
be partially due to sampling times as observed tmax and Cmax data were taken from the 
sampled data instead of extrapolation of the sampled point and therefore may not reflect the 
actual peak values. The estimation of tmax is complicated by the administration of 
bumetanide as a slow intravenous infusion. 
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Model Simulations of Brain Bumetanide in Pediatric Populations 
The Kp brain was first estimated using Rodgers and Rowland mechanistic method in Simcyp, 
which predicts drug distribution from physicochemical properties and in vitro data: this gave 
a predicted Kp brain in the pediatric population of 0.058. While Kp brain could have been 
estimated from previous in vitro experiments in which apparent permeability of bumetanide 
was measured (Maria D. Donovan, Harriët Schellekens, Geraldine B. Boylan, John F. Cryan, 
& Brendan T. Griffin, 2016), in vitro models have been noted to be poor at predicting of in 
vivo distribution of drugs and a battery of in vitro models would be required for accuracy 
(Garberg et al., 2005). If brain bumetanide concentrations in adults were available to verify 
predicted concentrations, a similar approach to that taken by Johnson et al., in which in vitro 
data was generated to determine apparent permeability and the efflux ratio of antipsychotics 
at the BBB, could be utilised to determine bumetanide permeability at the human BBB (M. 
Johnson et al., 2016). It has been proposed that animal data on Kp can be incorporated into a 
PBPK model to ensure accurate distribution if such information is available (Musther et al., 
2015). Kp brain values are available in the literature for bumetanide in rat (Kp 0.01 (Donovan 
et al., 2015)), mouse (Kp 0.015 (Tollner et al., 2015)) and rats with seizures (Kp 0.06-0.26, 
Donovan, O’Driscoll et al., unpublished (Brandt et al., 2010)). An estimation of total 
bumetanide concentration in brain mass was achieved by using each of these reported 
plasma: brain values to predict total brain bumetanide concentrations (Figure 5 and Table 5). 
Across the four doses administered to neonates, there was a 14-fold difference between the 
Cmax achieved when Kp brain was 0.01 compared to 0.26. The predicted Cmax in brain 
ranged from 0.0043 mg/L to 0.361 mg/L. These Cmax concentrations represent predictions of 
total brain concentrations of bumetanide; however, by taking into account that bumetanide 
has been shown to be highly brain-tissue bound (77% bound), the only predicted 
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concentration which achieves pharmacologically relevant unbound concentrations (0.073 
mg/L and 0.109 mg/L) is 0.361mg/L.  
 
Discussion 
The main objective of this study was to investigate if an in silico PBPK model could be used 
to predict bumetanide concentrations accurately in plasma and brain tissue in neonates with 
seizures. PBPK modeling is a method for the prediction of temporal drug concentrations in 
various organs, including the CNS (Wyska, Swierczek, Pociecha, & Przejczowska-Pomierny, 
2015). Using PBPK, it is possible to gain a prospective mechanistic understanding of the 
pharmacokinetics of a drug in the pediatric population, which facilitates optimal pediatric 
clinical trial design (Bjorkman, 2005). PBPK predictions in neonates are acknowledged to be 
difficult due to the rapidly evolving physiology in this age-group, including the changes in 
volume of distribution, hepatic and kidney function, and remodeling of the vasculature, 
leading to large inter-individual variability, as demonstrated in the predictions reported here 
(Bjorkman, 2005). Nonetheless, it may be possible to define a systemic dose of bumetanide 
that would be predicted to lead to pharmacologically relevant unbound concentrations in the 
brain using in silico PBPK models.  
There are reports of the successful use of PBPK in the prediction of pediatric 
pharmacokinetics and plasma concentration time profiles of oseltamivir (Parrott et al., 2011), 
clobazam and stiripentol (Ogungbenro & Aarons, 2015), valproic acid (Ogungbenro & 
Aarons, 2014), voriconazole (Zane & Thakker, 2014), quetiapine (T. N. Johnson et al., 2014), 
theophylline and midazolam (Bjorkman, 2005), cyclosporine (Gerard et al., 2010), 
moxifloxacin (Edginton, 2011), sotalol (Khalil & Läer, 2014), acetaminophen ((Jiang, Zhao, 
Barrett, Lesko, & Schmidt, 2013), lorazepam (Maharaj, Barrett, & Edginton, 2013), 
theophylline, sildenafil and phenytoin (Abduljalil, Jamei, Rostami-Hodjegan, & Johnson, 
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2014), paracetamol, alfentanil, morphine, theophylline and levofloxacin (Edginton, Schmitt, 
& Willmann, 2006). Even though many of the aforementioned drugs are used for disorders of 
the CNS, total and/or free drug concentrations in the brain are not reported or verified against 
animal or human data in these studies. This highlights the paucity of information available on 
the pharmacologically-relevant concentrations at the site of action of many neuroactive drugs 
in humans. Following verification of the bumetanide PBPK model built for this study using 
observed human adult data, bumetanide plasma/brain concentration profiles were predicted in 
a pediatric and a neonatal population. Predicted concentration-time plasma profiles in 
pediatrics and neonates were compared to available published data and concentration-time 
profiles shared with the group by the NEMO consortium, respectively. NEMO, a dose-
finding clinical study in neonates, investigated the effect of administering up to four doses of 
bumetanide 0.05mg/kg-0.3mg/kg at 12-hourly intervals on seizure control and reported an 
adverse benefit: risk ratio, which is likely to be partially due to low concentrations of 
bumetanide reaching the brain (Pressler et al., 2015).   
It is imperative that concentrations of neuroactive drugs at the site of action can be predicted, 
as they may differ greatly from exposure in other compartments due to a variety of factors 
including tissue volume, biochemical composition, active transport processes and metabolic 
clearance (de Lange, Ravenstijn, Groenendaal, & van Steeg, 2005; Kielbasa & Stratford, 
2012). The accurate prediction of drug concentrations in the human CNS from preclinical in 
vitro and in vivo data is known to be a challenging task (Westerhout, Ploeger, Smeets, 
Danhof, & de Lange, 2012). It has previously been shown that a bottom-up whole body 
PBPK modeling program simulated total brain concentrations accurately in rats (Ball, 
Bouzom, Scherrmann, Walther, & Decleves, 2014). In this study, both predicted and reported 
Kp brain values from rodent preclinical models were used to estimate total brain concentration 
of bumetanide in humans, since these values are not available for human populations (Brandt 
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et al., 2010; Donovan et al., 2015; Tollner et al., 2015). Given that the half-maximal 
inhibitory concentration of bumetanide for inhibition of NKCC1 is between 200nM and 
300nM, the unbound concentration of bumetanide achieved in brain has to be within this 
range for efficacy as a neuro-active therapeutic agent, thus free bumetanide in the brain 
should be present at concentrations between 0.073mg/L and 0.109mg/L (Puskarjov et al., 
2014). As bumetanide displays high non-specific binding to brain tissue, we have calculated 
that only one of the brain mass concentrations in Table 5 is likely to result in 
pharmacologically relevant levels of unbound bumetanide in brain i.e. a dose of 0.3mg/kg 
given to a neonate with a Kp brain of 0.26 (M. D. Donovan et al., 2016; Puskarjov et al., 2014). 
There are many limitations with this approach, including that Kp brain is only measured at a 
singular time-point and the output displays total brain tissue concentration as opposed to the 
unbound active concentration. Furthermore, it should be noted that only one neonate received 
the highest dose of 0.3mg/kg, and was administered three of the four possible doses at 12-
hourly intervals (Pressler et al., 2015). While no rescue antiepileptic medicines were required 
in this participant indicating drug efficacy, adverse effects of dehydration and hearing loss, 
which are at least partially bumetanide-related, were reported (Pressler et al., 2015). 
 
Following assessment of this in silico model’s predictions, we can cautiously postulate that 
the concentration of bumetanide reaching the CNS in the neonates enrolled in NEMO was 
sub-therapeutic. Strategies which can increase unbound concentrations of bumetanide in the 
brain in a safe and effective manner, such as OAT3 efflux transporter inhibition or prodrug 
administration need further exploration (Donovan et al., 2015; M. D. Donovan et al., 2016; 
Erker et al., 2016; Tollner et al., 2015; Tollner et al., 2014) However, close monitoring would 
be required in either of these scenarios to ensure any risk of toxicity is minimized as all of 
these simulations were carried out retrospectively and fitted to clinical data (Edginton et al., 
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2006). In silico models are a useful preclinical tool for estimation of concentrations in 
pediatric and neonatal populations; however, the paucity of physiological and transporter data 
in critically ill neonates with seizures, along with a lack of adult data, means that currently, 
the PBPK model developed here is not sufficiently robust to be used to completely bridge the 
knowledge gap between in vitro and in vivo studies to first-in-neonate dosing of bumetanide. 
This research has clearly shown that in silico prediction depends on the model input 
information and reflects the unmet need for the in-depth study of neonatal physiology, 
pharmacokinetics and pharmacodynamics to understand the kinetics and pharmacological 
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Table 1 Summary of bumetanide physicochemical properties and pharmacokinetic 
parameters used for model development in Simcyp. 
Parameter Input to Human Model 
 
Molecular weight (g/mol) 364.4 
Compound type Diprotic Acid 
LogP 2.6  
pKa1 3.6 (Fiori et al., 2003) 
pKa2 7.7 (Fiori et al., 2003) 
Blood to plasma ratio 0.55 (estimated, weak acid   1-haematocrit) 
Distribution model Full PBPK model 
Prediction model Rodgers and Rowland (method 2) 
Fraction unbound in plasma 
(fu) 
0.03 (Shim, Lee, & Lee, 1991) 
Total intravenous (IV) 
Clearance (Cl) 
10.17 L/h (Weighted mean from intravenous clearance reported in 
(Marcantonio et al., 1982; Oberbauer et al., 1995; Pentikainen et al., 
1985)) 
Renal Clearance  4.84 L/h (Marcantonio et al., 1982; Oberbauer et al., 1995)  




17.14 (calculated using retrograde model from intravenous clearance) 
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Table 2 Summary of predicted versus observed bumetanide pharmacokinetic parameters in 
the adult population after single intravenous doses  
Observed 
data 
AUC (ng/ml.h) Tmax (h) Cmax (ng/ml) 
 Pred Obs Pred/Obs  
Ratio 
Pred Obs Pred/Obs  
Ratio 
Pred Obs Pred/Obs  
Ratio 
Lau et al.: 
(Lau et al., 
1986) 
5mg IV bolus 
492 635 0.77 0.04 0.05 0.8 847 1375 0.62 
Cook et al.: 
(Cook et al., 
1988) 
3mg IV bolus  




et al., 1982) 












48.7 56.4 0.86 0.04 0.04 1 83.7 100 0.84 
Holazo et al.: 
(Holazo et al., 
1984) 
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Table 3 Summary of predicted versus observed bumetanide pharmacokinetic parameters in 
the pediatric population after single intravenous doses  
Observed data AUC (mcg/ml.min) Tmax (h) Cmax (mcg/ml) 
 Pred Obs Pred/Obs  
Ratio 
Pred Obs Pred/Obs  
Ratio 
Pred Obs Pred/Obs  
Ratio 
Marshall et al.: 







of adult IV 
clearance,  slow 
ontogeny 
36.24 36.1 1 0.04 0.04 1 1.32 0.95 1.39 
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Table 4 Summary of predicted versus observed bumetanide pharmacokinetic parameters in 
the neonatal population after multiple slow intravenous infusions  
Observed 
data 
AUCt first dose (mg/L.h) Tmax* (h) Cmax (mcg/ml) 
 Pred Obs Pred/Obs  
Ratio 
Pred Obs Pred/Obs  
Ratio 
Pred Obs Pred/Obs  
Ratio 
Jullien et al., 
2015(Jullien 




mean of adult 



























0.33-3.06 0.72 0.95 0.76 2.38 1.06 2.24 
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Table 5 Summary of maximum brain tissue concentration of bumetanide predicted with four 
Kp brain values 
Dose bumetanide 
administered 
Cmax brain (mg/L) 
Kp 0.01 Kp 0.015 Kp 0.058 Kp 0.26 
0.05mg/kg  0.0043 0.0066 0.024 0.0602 
0.1mg/kg 0.0087 0.013 0.048 0.12 
0.2mg/kg 0.0173 0.0263 0.0959 0.241 
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Figure 1 Workflow of bumetanide model development and verification in Simcyp
®
. IV = 
intravenous. Plasma concentrations from all populations used for validation were found in the 
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Figure 2 Predicted versus observed bumetanide pharmacokinetic profiles in the adult 
population after single intravenous doses A) Cook et al. trial, B) Oberbauer et al. trial, C) 
Holazo et al. trial, D) Marcantonio et al. trial and E) Lau et al. trial. Retrograde CLint 
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Figure 3 Predicted versus observed bumetanide pharmacokinetic profiles in a pediatric 
population (Marshall et al. trial) after single intravenous doses. Retrograde CLint calculated 
from weighted mean of intravenous clearance reported in three studies and slow ontogeny 
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Figure 4 Predicted versus observed bumetanide pharmacokinetic profiles in a neonatal 
population after multiple (up to four) slow intravenous infusions at 12-hourly intervals 
(NEMO dose-finding trial) of A) 0.05mg/kg bumetanide, B) 0.1mg/kg bumetanide, C) 
0.2mg/kg bumetanide and D) 0.3mg/kg bumetanide. Plasma samples were drawn from each 
neonate in the observed trial at up to four different time-points. Retrograde CLint calculated 
from weighted mean of intravenous clearance reported in three studies and slow ontogeny 
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Figure 5 Predicted brain tissue concentrations of bumetanide following intravenous 
administration every 12 hours of A) 0.05mg/kg bumetanide, B) 0.1mg/kg bumetanide, C) 
0.2mg/kg bumetanide and D) 0.3mg/kg bumetanide in neonates. Kp brain values estimated 
from Simcyp and preclinical studies. 
 
